Japan’s Shionogi, AstraZeneca Sue Seven Generics For Violating Crestor Patent (Japan)
This article was originally published in PharmAsia News
Japan's Shionogi joined with AstraZeneca in suing seven makers of generic drugs for applying in the United States for a version of Crestor (rosuvastatin calcium) for lowering cholesterol. Shionogi, the developer, said its U.S. patent for the drug is still in effect and the application violates it. AstraZeneca markets the drug. Defendants in the suit are Apotex, Aurobindo Pharma, Cobalt Pharmaceuticals, Mylan Pharmaceuticals, Pan Pharmaceuticals, Sandoz and Sun Pharmaceuticals. (Click here for more - may require a subscription
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.